SAN DIEGO, April 14, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 - 20, 2016.
Data to be presented include in vitro studies of an anti-5T4 antibody drug conjugate (ADC), mechanistic studies of a co-stimulatory anti-TIM3 antibody, and preclinical studies of an anti-c-Met ADC in non-small cell lung cancer models.
Abstract Number: 1214
Presentation Title: Development of anti-5T4 antibody-drug conjugates, ZV05-ADCs for targeted cancer therapy in different type of cancers
Session Category: Experimental and Molecular Therapeutics
Session Date and Time: Monday Apr 18, 2016 8:00 AM - 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 15
Author Block: Zhaohui Li*, Hong Zhang#, Dylan Deng#, Tong Zhu#, Gang Chen#, Sheldon Cao*, David Miao#, *Zova Biotherapeutics, Inc., Hangzhou, Zhejiang, PR China, #Sorrento Therapeutics, Inc., San Diego, CA
Abstract Number: 3214
Presentation Title: A Fully Human Anti-TIM3 Antibody with Co-Stimulatory Activity
Session Category: Immune Checkpoints 2
Session Date and Time: Tuesday Apr 19, 2016 8:00 AM – 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 25
Author Block: J Dixon Gray, Irina Krapf, Heyue Zhou, Gunnar F. Kaufmann. Sorrento Therapeutics, Inc., San Diego, CA
Abstract Number: 3897
Presentation Title: A novel c-Met targeting antibody drug conjugate for NSCLC
Session Category: Cancer Chemistry
Session Date and Time: Tuesday Apr 19, 2016 1:00 PM - 5:00 PM
Location: Convention Center, Halls G-J, Poster Section 21
Author Block: Lingna Li, Katherine Fells, Julia Guo, Pia Muyot, Edwige Gros, Yanliang Zhang, Yingqing Sun, Hong Zhang, Yanwen Fu, Tong Zhu, Jian Cao, Gunnar F. Kaufmann,
Gang Chen, Zhenwei Miao. Sorrento Therapeutics, Inc., San Diego, CA
About Sorrento Therapeutics, Inc.
Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Sorrento's and its subsidiaries' prospects; Sorrento's expectations for its technologies and collaborations; Sorrento's and its subsidiaries' advances made in developing antibody drug conjugates (ADCs), human monoclonal antibodies using its proprietary G-MAB fully human antibody technology and any of their other respective technologies, if any; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
All other trademarks and trade names are the property of their respective owners.
© 2016 Sorrento Therapeutics, Inc. All Rights Reserved.
SOURCE Sorrento Therapeutics, Inc.